A 63-year-old man with type 2 diabetes, established coronary artery disease and an eGFR of 55 mL/min/1.73 m² has HbA1c 7.8% on maximally tolerated metformin. According to Diabetes Canada, which class of agent should be prioritised next for cardiovascular and renal benefit?